Drug Trial Radar · NCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 5, 2026
Primary completion
Jun 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- Camurus ABIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2026
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
Conditions
- Acromegaly
Interventions
Octreotide subcutaneous depotDrug
Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.Time frame: From enrollment to the end of treatment at 2 years
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Universitaetsklinikum Aachen
Aachen, Germany · Recruiting
Universitaetsklinikum Leipzig
Leipzig, Germany · Recruiting
Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
Magdeburg, Germany · Recruiting
Medicover Neuroendokrinologie MVZ
München, Germany · Not yet recruiting
Universitätsklinikum Münster
Münster, Germany · Not yet recruiting
Universitätsklinikum Würzburg
Würzburg, Germany · Recruiting
St James's University Hospital - Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.